Statement: There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.
Primary_evidence: Adverse Events 1:   Total: 111/669 (16.59%)   Leukocytes *  [1]1/669 (0.15%)   Hemoglobin *  [1]1/669 (0.15%)   Hemoglobin *  [2]0/669 (0.00%)   CNS cerebrovascular ischemia *  [1]0/669 (0.00%)   CNS cerebrovascular ischemia *  [3]0/669 (0.00%)   Heart Failure *  [1]3/669 (0.45%)   Thrombosis/embolism *  [1]1/669 (0.15%)   Thrombosis/embolism *  [3]0/669 (0.00%) Adverse Events 2:   Total: 138/715 (19.30%)   Leukocytes *  [1]0/715 (0.00%)   Hemoglobin *  [1]0/715 (0.00%)   Hemoglobin *  [2]1/715 (0.14%)   CNS cerebrovascular ischemia *  [1]1/715 (0.14%)   CNS cerebrovascular ischemia *  [3]1/715 (0.14%)   Heart Failure *  [1]1/715 (0.14%)   Thrombosis/embolism *  [1]3/715 (0.42%)   Thrombosis/embolism *  [3]2/715 (0.28%)